The Study
Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.
This article is like a summary of other scientists' work—it doesn't do new experiments. It says, 'Here's what other studies have found about how some body chemicals might be linked to diabetes in women with PCOS.' But it doesn't prove anything causes anything—it just points out patterns others saw.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
Even if a woman with PCOS looks thin, her body might be storing fat inside her belly and struggling to use sugar properly — and standard tests like BMI miss this.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means many women are at high risk for diabetes even if they don't look overweight, and current screening misses them.
- 220–30% of PCOS cases in South Asian women are 'lean' (BMI <23), but 44–70% of them still have insulin resistance — meaning their bodies can't handle sugar well, even without being overweight.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Best practice & research. Clinical endocrinology & metabolism
Year
2026
Authors
P. Wangikar, K. Vinodkumar, K. Agarwal, A. Sunder, Deepti Sahasrabuddhe, Bharati Kulkarni, M. S. Kamath, Neena Malhotra, Nitin Kapoor
Related Content
Claims (7)
South Asian women with PCOS often have insulin resistance and higher cardiometabolic risk even when their body mass index is below 23 kg/m², a threshold at which Western populations are not typically considered at risk, meaning BMI alone misses metabolic danger in this group.
Metabolomics analysis of women with polycystic ovary syndrome can detect distinct metabolic patterns that accurately forecast future development of type 2 diabetes and obesity, allowing risk assessment that improves upon standard clinical measures.
Standard medical tests like BMI, blood sugar, and hormone levels do not detect all cases of insulin resistance and heart disease risk in women with polycystic ovary syndrome, especially those who are lean or have fat around the waist and are of South Asian descent.
In patients with PMOS, weight gain occurs as a result of metabolic dysfunction.
Women with polycystic ovary syndrome show distinct patterns in blood metabolites related to amino acids, fats, bile acids, and steroid compounds, and these patterns better predict future risk of type 2 diabetes and obesity than traditional measures like body mass index or androgen levels.
In South Asian women with polycystic ovary syndrome, specific genetic variations in insulin, steroid, and obesity-related genes are more common or have stronger effects, resulting in earlier and more severe cardiometabolic problems.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.